Matt Zuga - 29 Dec 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: CFO and Chief Business Officer
Signature: /s/ Katherine Denby, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 29 Dec 2022
Transactions value $: $59,500
Form type: 4
Filing time: 03 Jan 2023, 16:23:33 UTC
Previous filing: 21 Jan 2022
Next filing: 18 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Options Exercise	$59.5K	+50K	+190.93%	$1.19	76.2K	29 Dec 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (right to buy)	Options Exercise	$0	-50K	-11.08%	$0.00	401K	29 Dec 2022	Common Stock	50K	$1.19	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying the option vested and became exercisable on January 1, 2022; the remainder vested or shall vest and become exercisable in 36 equal monthly installments such that the option shall be fully vested on January 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each such date.